compound 5f

**Compound 5f** is an experimental **coumarin-6-sulfonamide-chalcone hybrid** reported in a 2024 medicinal chemistry study as a **small-molecule inhibitor of human glutathione transferase P1-1**. In the cited enzyme assay series, compound 5f was among the most active analogs, showing an **IC50 of 12.7 μM** against hGSTP1-1, a detoxification enzyme implicated in tumor multidrug resistance. The same publication also evaluated 5f in vitro against human prostate cancer cell lines DU-145 and PC3 and the breast cancer cell line MCF-7, where it showed cytotoxic activity, although it was not the lead compound of the series. No clinical development, proprietary non-code name, developer company, formulation, route, or commercial status was identified from the provided evidence.

Other names

coumarin-6-sulfonamide-chalcone hybrid 5fcoumarin6-sulfonamide-chalcone hybrid 5fcoumarin 6-sulfonamide-chalcone hybrid 5f